Atai Beckley

AtaiBeckley is a clinical-stage biopharmaceutical company formed in November 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. The company is a global leader in the development of psychedelic-based neuroplastogens and other innovative therapeutics for mental health disorders. Its diversified pipeline features several mid-to-late-stage programs, including BPL-003 (intranasal mebufotenin) for treatment-resistant depression, VLS-01 (buccal film DMT) for depression, and EMP-01 (oral R-MDMA) for social anxiety disorder. By leveraging a decentralized platform model, AtaiBeckley aims to accelerate the delivery of rapid-acting, effective, and convenient treatments to patients suffering from conditions such as depression, anxiety, and schizophrenia. The company is headquartered in New York and is publicly traded on the NASDAQ under the symbol ATAI.